FDA Contradicts Trump Administration on Autism Drug Approval

The FDA declined to approve a generic drug for autism despite pressure from the Trump administration, citing insufficient data for the broader condition. The agency only approved the drug for a rare genetic variant, contradicting the administration's push for broader access. This decision highlights ongoing tensions between executive mandates and independent regulatory scientific standards.